BACKGROUND: We investigated whether individuals with positive coeliac disease antibodies but without small-bowel villous atrophy have mucosal inflammation implicating gluten-sensitivity. METHODS: Small-bowel mucosal morphology; CD3+, alphabeta+, and gammadelta+ T-cell receptor-bearing intraepithelial lymphocytes; and mucosal HLA-DR expression were studied in 96 IgA-class antireticulin or antigliadin antibody-positive adults suspected of having coeliac disease and in 27 control subjects. RESULTS: Villous atrophy compatible with coeliac disease was found in altogether 29 patients, in 18 of 21 (86%) patients with both antireticulin and antigliadin antibodies, in 9 of 15 (60%) patients with antireticulin antibodies only, and in 2 of 60 (3%) with antigliadin antibodies only. In 67 antibody-positive patients with normal villous architecture the densities of CD3+, alphabeta+, and gammadelta+ intraepithelial lymphocytes were significantly higher than in non-coeliac control subjects. Ten patients with initially increased densities of gammadelta+ T cells but normal villous structure underwent a follow-up biopsy after 4-18 months, which showed villous atrophy in five patients. CONCLUSIONS: IgA-class antireticulin or antigliadin antibody-positive patients with normal small-bowel mucosal morphology frequently have immunohistochemical markers of coeliac disease latency. Together with our follow-up data this implies that they may be gluten-sensitive.
BACKGROUND: We investigated whether individuals with positive coeliac disease antibodies but without small-bowel villous atrophy have mucosal inflammation implicating gluten-sensitivity. METHODS: Small-bowel mucosal morphology; CD3+, alphabeta+, and gammadelta+ T-cell receptor-bearing intraepithelial lymphocytes; and mucosal HLA-DR expression were studied in 96 IgA-class antireticulin or antigliadin antibody-positive adults suspected of having coeliac disease and in 27 control subjects. RESULTS:Villous atrophy compatible with coeliac disease was found in altogether 29 patients, in 18 of 21 (86%) patients with both antireticulin and antigliadin antibodies, in 9 of 15 (60%) patients with antireticulin antibodies only, and in 2 of 60 (3%) with antigliadin antibodies only. In 67 antibody-positive patients with normal villous architecture the densities of CD3+, alphabeta+, and gammadelta+ intraepithelial lymphocytes were significantly higher than in non-coeliac control subjects. Ten patients with initially increased densities of gammadelta+ T cells but normal villous structure underwent a follow-up biopsy after 4-18 months, which showed villous atrophy in five patients. CONCLUSIONS: IgA-class antireticulin or antigliadin antibody-positive patients with normal small-bowel mucosal morphology frequently have immunohistochemical markers of coeliac disease latency. Together with our follow-up data this implies that they may be gluten-sensitive.
Authors: L Greco; R Romino; I Coto; N Di Cosmo; S Percopo; M Maglio; F Paparo; V Gasperi; M G Limongelli; R Cotichini; C D'Agate; N Tinto; L Sacchetti; R Tosi; M A Stazi Journal: Gut Date: 2002-05 Impact factor: 23.059
Authors: David S Sanders; David P Hurlstone; Mark E McAlindon; Marios Hadjivassiliou; Simon S Cross; Graeme Wild; Christopher J Atkins Journal: BMJ Date: 2005-04-02
Authors: Manuel A Silva; Jennifer Jury; Yolanda Sanz; Michelle Wiepjes; Xianxi Huang; Joseph A Murray; Chella S David; Alessio Fasano; Elena F Verdú Journal: Dig Dis Sci Date: 2011-08-07 Impact factor: 3.199
Authors: Marjorie M Walker; Joseph A Murray; Jukka Ronkainen; Pertti Aro; Tom Storskrubb; Mauro D'Amato; Brian Lahr; Nicholas J Talley; Lars Agreus Journal: Gastroenterology Date: 2010-04-13 Impact factor: 22.682
Authors: A I Lahdenperä; V Hölttä; T Ruohtula; H M Salo; L Orivuori; M Westerholm-Ormio; E Savilahti; K Fälth-Magnusson; L Högberg; J Ludvigsson; O Vaarala Journal: Clin Exp Immunol Date: 2012-02 Impact factor: 4.330
Authors: Liisa Viitasalo; Laura Niemi; Merja Ashorn; Sara Ashorn; Jonathan Braun; Heini Huhtala; Pekka Collin; Markku Mäki; Katri Kaukinen; Kalle Kurppa; Sari Iltanen Journal: J Clin Gastroenterol Date: 2014-08 Impact factor: 3.062